

12th Annual Course

Madrid, Spain

March 08th - 09th, 2013

Chair: M. Dicato, H. Ludwig, P. Gascon Course co-ordinator: M. Aapro

Advisor: C. Bokemeyer

In collaboration with



EORTC Anaemia Working Party

ANAEMIA NEUTROPENIA THROMBOCYTOPENIA AND CANCER COURSE

Friday, March 08th, 2013

	10:00	Registrations Open
1	2:00-13:00	Buffet Lunch
13	3:00-13:10	Welcome: Chairmen and Coordinator
13	3:10-14:05	SESSION 1: Anaemia in Cancer Patients Chairman: <i>H. Ludwig</i>
1	3:10-13:25	Pathophysiology and incidence of anaemia in cancer patient <i>T. Littlewood</i>
1	3:30-13:45	Safety and efficacy of red blood cell transfusions - K. Zacharowski
1	3:50-14:05	Alternatives to ESAs and iron? - J. Glaspy
14	4:10-15:25	SESSION 2: Neutropenia in Cancer Patients Chairman: <i>M. Aapro</i>
1	4:10-14:25	EORTC and other guidelines for G-CSF usage. Where do we stand? <i>P. Pronzato</i>
1	4:30-14:40	A case discussion - M. Aapro
1	4:45-15:05	Models for FN risk assessment - G. Lyman
1	5:10-15:25	What to do if FN hits: patient evaluation and empirical antibiotics $\it J.~Mu\~noz~Langa$
15	5:30-15:50	Special lecture: The Lancet commission and ESO's World Oncology Forum: priorities in cancer care - <i>R. Sullivan</i>
16	6:00-16:30	BREAK
16	5:30-17:40	SESSION 3: Iron and Cancer Patients Chairman: <i>H. Ludwig</i>
1	6:30-16:35	Patient case - M. Aapro
1	6:40-17:00	Pathophysiology of iron deficiency in cancer patients and the role of hepcidin - Y. Beguin

THROMBOCYTOPENIA AND CANCER COURSE

	Friday, March 08th, 2013
17:05-17:20	Iron, anaemia and chemotherapy: what to do in daily practice? H. Ludwig
17:25-17:40	How safe is iron in patients with cancer? - A. Österborg
17:45-19:00	SESSION 4: Hemostasis Chairman: <i>M. Dicato</i>
17:45-17:55	Treatment of thrombocytopenia: when are platelets needed? M. Dicato
18:00-18:20	Personalizing cancer-associated venous thrombosis prevention: patient risk factors and biomarkers - <i>N. Kuderer</i>
18:25-18:40	Thromboprophylaxis in ambulatory cancer patients with or without in-dwelling catheter - M.Mandalà
18:45-19:00	New oral anticoagulants: practical tips for use - M. Dicato
19:00	Closure of the day
	Saturday, March 09th, 2013
08:30	Saturday, March 09 th , 2013 Opening of the day: course chairs
08:30 08:40-09:15	
	Opening of the day: course chairs SESSION 5: About EPO in 2013
08:40-09:15	Opening of the day: course chairs SESSION 5: About EPO in 2013 Chairman: <i>P. Gascon</i> Safety update on EPOs in chemotherapy treated cancer patients
08:40-09:15 08:40-08:55	Opening of the day: course chairs SESSION 5: About EPO in 2013 Chairman: P. Gascon Safety update on EPOs in chemotherapy treated cancer patients M. Aapro
08:40-09:15 08:40-08:55 09:00-09:15	Opening of the day: course chairs SESSION 5: About EPO in 2013 Chairman: P. Gascon Safety update on EPOs in chemotherapy treated cancer patients M. Aapro Early EPO intervention, better result, less loss - P. Gascon SESSION 6: Supportive care questions
08:40-09:15 08:40-08:55 09:00-09:15 09:20-10:05	Opening of the day: course chairs SESSION 5: About EPO in 2013 Chairman: P. Gascon Safety update on EPOs in chemotherapy treated cancer patients M. Aapro Early EPO intervention, better result, less loss - P. Gascon SESSION 6: Supportive care questions Chairman: M. Dicato

NEUTROI

Saturday, March 09th, 2013

10:40-11:00	Special Lecture The nurse, the patient and supportive care issues: EONS representative - R. Taberner Hermosilla
11:00-12:05	SESSION 7: Anaemia beyond solid tumours Chairman: <i>M. Aapro</i>
11:00-11:15	Role of EPOs in lymphoma (Hodgkin's and non-Hodgkin's) - J. Glaspy
11:20-11:40	EPO in MDS - V. Santini
11:45 -12:05	Conventional and investigative approaches in management of anaemia in myeloma - <i>H. Ludwig</i>
12:10- 12:25	LEARNING ASSESSMENT (LA) FOR CME
12:30	CME certificates given only to those participants who have completed the LA

Chair

12:30-13:30 Buffet Lunch

Mario Dicato Heinz Ludwig Pere Gascon

Course Co-ordinator

Matti Aapro

Advisor

Carsten Bokemeyer

Faculty

Matti Aapro - CH Yves Beguin - B Paul Cornes - UK Mario Dicato - L Pere Gascon - E John Glaspy - USA Didier Kamioner - F Nicole Kuderer - USA Tim Littlewood - UK Heinz Ludwig - A Gary Lyman - USA Mario Mandalà - I José Muñoz Langa - E Anders Österborg - SE Paolo Pronzato - I Valeria Santini - I Richard Sullivan - UK Remedios Taberner Hermosilla - E Kai Zacharowski - D

ANAEMIA NEUTROPENIA THROMBOCYTOPENIA AND CANCER COURSE

Course venue

Hotel Meliá Avenida América

Juan Ignacio Luca de Tena, 36 28027 Madrid, Spain Phone: +34 91 4232413

Topics covered during the course

- Basic facts about anaemia, neutropenia and thrombocytopenia
 Short review of normal myelopoiesis
 Pathophysiology of anaemia in cancer
 Incidence of anaemia in cancer
 Importance of neutropenia in cancer
 Importance of thrombocytopenia in cancer
 Thrombosis in cancer
- Symptoms and consequences of anaemia, neutropenia and thrombocytopenia

Clinical symptoms - quality of life
Consequences of anaemia on tumour progression and prognosis
Consequences of neutropenia
Consequences of thrombocytopenia
Prevention of thrombosis in cancer patients

Treatment of anaemia and neutropenia in cancer patients
 Predicting risk of anaemia during chemotherapy
 Transfusions: pros and cons

Erythropoietin and iron:

Clinical results

Impact on haemoglobin

Impact on transfusion frequency

Impact on quality of life

Impact on outcome

Prediction of response

Economic aspects and biosimilars

How to use them properly

Updated EORTC G-CSF use guidelines

Present and future developments

THROMBOCYTOPENIA AND CANCER COURSE

Objectives of the course

This course should clarify issues related to anaemia and neutropenia in the cancer patient and the optimal way of preventing or treating these problems, including a review of EORTC guidelines for anaemia and neutropenia management. It will also focus on aspects still unresolved in the treatment of cancer treatment-associated anaemia like management of iron, discussed with participation from the audience. At the end of the course the participants should be able to better prescribe preventative or corrective actions in these areas for cancer patients and critically follow the development of this important field in the near future.

Official language

The official language of the course is English

CME information

Each participant will receive a certificate of attendance stating the relevant number of credits obtained during the conference.

The CME certificates can be granted only to the participants who have attended the entire conference.

The CME certificates will be distributed only at the end of the meeting.

Organising secretariat

Vision Plus Srl

P.zza San Pietro Martire, 6 - 20900 Monza (MB) - Italy

Phone +39 039 2326183 - Fax +39 039 3309918

Email: medicaleducation@visionplus.it